Rohan Palekar, 89bio CEO
March 22, 2023 07:00 AM EDTUpdated 02:12 PM
R&D

89bio’s PhII da­ta add to quick suc­ces­sion of NASH read­outs as field seeks turn­around

Kyle LaHucik

Senior Reporter

89bio said its drug was bet­ter than place­bo at less­en­ing fi­bro­sis with­out wors­en­ing non­al­co­holic steato­hep­ati­tis, or NASH, in two of three …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times